CSL Behring’s new plasma processing facility in Melbourne has been named the 2025 Facility of the Year in the Pharma 4.0 category by the International Society for Pharmaceutical Engineering.
This award recognises the facility’s advanced design and utilisation of digital technologies to enhance the production of medicines.
The fully operational site is the world's largest plasma fractionation facility of its kind. It has boosted CSL Behring’s capacity in Australia by nine times, now processing over 10 million litres of plasma each year. This helps CSL produce key components for therapies used to treat immune disorders, bleeding conditions like haemophilia and trauma-related injuries.
The facility utilises modern automation, robotics, and a 'digital twin' – a virtual replica of the plant – to enhance safety, minimise waste, and optimise operations. Its modular design allows for flexible upgrades and maintenance, helping CSL keep pace with future technology and patient needs.
Laura O’Brien, CSL Behring's head of global manufacturing, said, “Projects like our Broadmeadows Plasma Fractionation Facility enable us to meet patients' needs with greater flexibility and efficiency. This initiative not only enhances our plasma processing capabilities but also sets a new standard for future projects across our global manufacturing network. Being announced the category winner for Pharma 4.0 underscores our commitment to innovation and transformation in pharmaceutical manufacturing.
“We are honored to be recognised by ISPE and will continue to push the boundaries of pharmaceutical manufacturing by integrating advanced technologies and sustainable practices for the benefit of patients worldwide”.
Andrew Hodder, the manufacturing and site head at CSL Behring Broadmeadows, added, “The modular design approach, advanced automation and digital twin technology, combined with our commitment to environmental sustainability, have transformed our operations and expanded patient access to lifesaving plasma therapies globally. This facility builds on our proud Australian heritage and represents a bright future for our Broadmeadows site and biopharma manufacturing in Australia."
